JPWO2021228141A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021228141A5 JPWO2021228141A5 JP2022568760A JP2022568760A JPWO2021228141A5 JP WO2021228141 A5 JPWO2021228141 A5 JP WO2021228141A5 JP 2022568760 A JP2022568760 A JP 2022568760A JP 2022568760 A JP2022568760 A JP 2022568760A JP WO2021228141 A5 JPWO2021228141 A5 JP WO2021228141A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- seq
- sequence
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023213677A JP7734178B2 (ja) | 2020-05-15 | 2023-12-19 | 抗体薬物複合体、その調製方法、およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010410633.5 | 2020-05-15 | ||
| CN202010410633 | 2020-05-15 | ||
| PCT/CN2021/093348 WO2021228141A1 (zh) | 2020-05-15 | 2021-05-12 | 抗体药物缀合物及其制备方法和用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023213677A Division JP7734178B2 (ja) | 2020-05-15 | 2023-12-19 | 抗体薬物複合体、その調製方法、およびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023525120A JP2023525120A (ja) | 2023-06-14 |
| JP2023525120A5 JP2023525120A5 (https=) | 2023-08-15 |
| JPWO2021228141A5 true JPWO2021228141A5 (https=) | 2023-08-15 |
| JP7407973B2 JP7407973B2 (ja) | 2024-01-04 |
Family
ID=78525267
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568760A Active JP7407973B2 (ja) | 2020-05-15 | 2021-05-12 | 抗体薬物複合体、その調製方法、およびその使用 |
| JP2023213677A Active JP7734178B2 (ja) | 2020-05-15 | 2023-12-19 | 抗体薬物複合体、その調製方法、およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023213677A Active JP7734178B2 (ja) | 2020-05-15 | 2023-12-19 | 抗体薬物複合体、その調製方法、およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230338565A1 (https=) |
| EP (1) | EP4151235A4 (https=) |
| JP (2) | JP7407973B2 (https=) |
| KR (1) | KR20230012000A (https=) |
| CN (1) | CN115715202B (https=) |
| AU (1) | AU2021270940A1 (https=) |
| CA (1) | CA3178406A1 (https=) |
| CL (2) | CL2022003170A1 (https=) |
| CO (1) | CO2022016208A2 (https=) |
| CR (1) | CR20220580A (https=) |
| DO (1) | DOP2022000251A (https=) |
| EC (1) | ECSP22089507A (https=) |
| GE (2) | GEP20257719B (https=) |
| IL (1) | IL298184A (https=) |
| JO (1) | JOP20220306A1 (https=) |
| MX (1) | MX2022014332A (https=) |
| PE (1) | PE20230373A1 (https=) |
| WO (1) | WO2021228141A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121873089A (zh) * | 2021-12-02 | 2026-04-17 | 四川科伦博泰生物医药股份有限公司 | 一种药物-接头偶联物的制备方法 |
| CN118434741A (zh) * | 2022-01-26 | 2024-08-02 | 苏州宜联生物医药有限公司 | 一种药物连接体偶联物的制备方法 |
| AU2023307126A1 (en) * | 2022-07-14 | 2025-02-13 | Medilink Therapeutics (Suzhou) Co., Ltd. | Antibody-drug conjugate, and preparation method therefor and use thereof |
| WO2024027708A1 (zh) * | 2022-08-02 | 2024-02-08 | 诺纳生物（苏州）有限公司 | Msln抗体药物偶联物 |
| EP4623936A1 (en) | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| MX2025009780A (es) * | 2023-02-24 | 2025-09-02 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Uso de un conjugado de farmaco en el tratamiento de una enfermedad tumoral y metodo |
| CN120615097A (zh) * | 2023-03-02 | 2025-09-09 | 普众发现医药科技(上海)有限公司 | 抗体药物偶联物、药物组合物及其用途 |
| CN119212735A (zh) * | 2023-04-27 | 2024-12-27 | 石药集团巨石生物制药有限公司 | 一种抗体药物偶联物 |
| AU2024263367A1 (en) * | 2023-04-27 | 2025-11-13 | CSPC Megalith Biopharmaceutical Co., Ltd. | Antibody-drug conjugate |
| EP4461317A1 (en) * | 2023-05-12 | 2024-11-13 | Emergence Therapeutics GmbH | Antibody-drug conjugates comprising an anti-nectin-4 antibody and belotecan or a derivative thereof |
| CN119139489A (zh) * | 2023-06-16 | 2024-12-17 | 信达生物制药(苏州)有限公司 | 靶向Claudin18.2的抗体-药物偶联物用于治疗实体瘤的方法 |
| CN117327182B (zh) * | 2023-09-19 | 2024-06-04 | 上海交通大学医学院附属仁济医院 | Cldn18.2单域抗体探针的制备方法及应用 |
| WO2025106278A1 (en) | 2023-11-17 | 2025-05-22 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| US9056092B2 (en) * | 2011-12-02 | 2015-06-16 | Ethicon, Inc. | Hemostatic bioabsorbable device with polyethylene glycol binder |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| SI2900277T1 (sl) * | 2012-12-13 | 2022-05-31 | Immunomedics, Inc. | Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost |
| KR102236367B1 (ko) | 2013-07-26 | 2021-04-05 | 삼성전자주식회사 | DARPin을 포함하는 이중 특이 키메라 단백질 |
| US10323095B2 (en) | 2014-03-17 | 2019-06-18 | Mitsubishi Tanabe Pharma Corporation | Antibody-fynomer conjugates |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| AU2017294276B2 (en) * | 2016-07-08 | 2024-08-01 | Crage Medical Co., Limited | Antibody for anti-claudin 18A2 and use thereof |
| EP3725798B1 (en) * | 2017-12-15 | 2026-03-04 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Bioactive conjugate, preparation method therefor and use thereof |
| CN110090308B (zh) * | 2018-01-30 | 2023-03-24 | 四川科伦博泰生物医药股份有限公司 | 制备偶联物的方法 |
| CN111542324B (zh) * | 2018-02-11 | 2023-09-12 | 四川科伦博泰生物医药股份有限公司 | 细胞毒性剂及其偶联物、其制备方法及用途 |
| US11485782B2 (en) * | 2018-03-14 | 2022-11-01 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
| CN111110862A (zh) * | 2018-11-01 | 2020-05-08 | 上海健信生物医药科技有限公司 | 抗cldn18．2抗体的药物偶联体及其制备方法和用途 |
| US11505618B2 (en) * | 2018-07-18 | 2022-11-22 | Askgene Pharma Inc. | Antibodies and methods for making and using the same |
| CN112770723B (zh) * | 2018-07-25 | 2024-08-02 | 阿克罗斯生物科学公司 | Cldn 18.2特异性单克隆抗体及其使用方法 |
| US12297265B2 (en) * | 2018-12-28 | 2025-05-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody and use thereof |
| US20230192903A1 (en) * | 2020-05-29 | 2023-06-22 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody against cldn18.2 and cd3 |
-
2021
- 2021-05-12 IL IL298184A patent/IL298184A/en unknown
- 2021-05-12 GE GEAP202116114A patent/GEP20257719B/en unknown
- 2021-05-12 CA CA3178406A patent/CA3178406A1/en active Pending
- 2021-05-12 EP EP21804105.1A patent/EP4151235A4/en active Pending
- 2021-05-12 GE GEAP202416114A patent/GEAP202416114A/en unknown
- 2021-05-12 WO PCT/CN2021/093348 patent/WO2021228141A1/zh not_active Ceased
- 2021-05-12 KR KR1020227043736A patent/KR20230012000A/ko active Pending
- 2021-05-12 CR CR20220580A patent/CR20220580A/es unknown
- 2021-05-12 JP JP2022568760A patent/JP7407973B2/ja active Active
- 2021-05-12 US US17/998,772 patent/US20230338565A1/en active Pending
- 2021-05-12 PE PE2022002658A patent/PE20230373A1/es unknown
- 2021-05-12 MX MX2022014332A patent/MX2022014332A/es unknown
- 2021-05-12 AU AU2021270940A patent/AU2021270940A1/en active Pending
- 2021-05-12 CN CN202180032620.1A patent/CN115715202B/zh active Active
-
2022
- 2022-11-10 JO JOJO/P/2022/0306A patent/JOP20220306A1/ar unknown
- 2022-11-11 CO CONC2022/0016208A patent/CO2022016208A2/es unknown
- 2022-11-14 CL CL2022003170A patent/CL2022003170A1/es unknown
- 2022-11-14 DO DO2022000251A patent/DOP2022000251A/es unknown
- 2022-11-21 EC ECSENADI202289507A patent/ECSP22089507A/es unknown
-
2023
- 2023-12-19 JP JP2023213677A patent/JP7734178B2/ja active Active
-
2024
- 2024-10-01 CL CL2024002956A patent/CL2024002956A1/es unknown